ProteoNic, NecstGen partner on viral vector manufacturing

By The Science Advisory Board staff writers

April 28, 2022 -- ProteoNic and NecstGen are partnering to develop improved viral vector manufacturing for gene therapy applications, specifically using adeno-associated virus (AAV) and lentivirus (LV) vectors.

ProteoNic will employ its 2G UNic technology to improve viral vector performance and NecstGen will contribute its viral vector platforms, manufacturing processes, and experts, the firms said.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.